Specify a stock or a cryptocurrency in the search bar to get a summary
Anthera Pharmaceuticals Inc
ANTHAnthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas. Address: The Pennzoil Building, Houston, TX, United States, 77002
Analytics
WallStreet Target Price
3 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ANTH
Dividend Analytics ANTH
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ANTH
Stock Valuation ANTH
Financials ANTH
Results | 2019 | Dynamics |